Chemicals

Amyris to Acquire Sweet Protein Developer Oobli

Soren LindqvistNovember 16, 20265 min read0 views

At a glance

  • The proposed deal pairs Amyris' fermentation manufacturing scale with Oobli's brazzein, monellin and thaumatin ingredient platforms.
  • Amyris has announced plans to acquire Oobli, a fermentation-based sweet protein developer, in a deal expected to close within weeks. The companies say the combination would add manufacturing scale to a sugar-reduction ingredient portfolio already cleared for use as a GRAS ingredient and natural flavor.
A stainless-steel fermentation vessel linked by translucent protein strands to a cluster of berries and a dissolving sugar cube in a cool-toned conceptual scene.

Amyris, Inc. (Emeryville, Calif.) has announced that it will acquire Oobli Inc. (Davis, Calif.), a developer of fermentation-derived sweet proteins that food and beverage brands use to cut sugar while keeping sweetness. The transaction is expected to close in the coming weeks.

Amyris framed the deal as a strategic commercial and technology expansion that combines its own scientific and manufacturing depth with Oobli's protein fermentation expertise. It follows the company's expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and is intended to accelerate its presence in protein- and peptide-based solutions across end markets.

Complementary platforms

Amyris chief executive Kathy Fortmann described Oobli as a commercial and technology platform that complements its own, and said Oobli is positioned to change how sweetness reaches the market. She added that combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial capabilities could broaden the company's reach in food and beverage, personal care, flavor and fragrance, agriculture and beyond.

Oobli's commercial portfolio is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process for producing sweet proteins found naturally in rare fruits and berries growing near the equator. According to the companies, sweet proteins are the first of their kind in the sugar-reduction category: hundreds to thousands of times sweeter than sugar, they bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.

The portfolio covers three proteins:

  • Oubli Fruit sweet protein (brazzein)
  • Serendipity Berry sweet protein (monellin)
  • Katemfe Fruit sweet protein (thaumatin)

The ingredients hold FDA GRAS status for use as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. With consumer awareness of metabolic health and the benefits of sugar reduction rising, the companies see potential applications spanning sports nutrition, dairy, beverages, chocolate, bakery and confectionery.

Scale for a broader standard

Oobli chief executive Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment, and that joining Amyris provides the scale and resources to pursue its ambition of making sweet proteins a standard sweetness solution.

Fortmann added that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform does so by addressing sweet taste, sugar reduction and clean label at the same time.

Amyris said all existing Oobli customer commitments and brand partnerships will continue to be honored without interruption as the sweet protein portfolio expands within the combined company.

Reported by Soren Lindqvist, Industrial Feedstocks, Safety and Process Chemicals Analyst.